Back to search results

A Study of Quabodepistat-containing Regimens for the Treatment of Drug-resistant Pulmonary Tuberculosis

Abroad (travel likely)RecruitingPHASE3

Conditions

Pulmonary Tuberculosis

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Capital Medical University - Beijing Chest Hospital, Beijing, Beijing Municipality, China

  • Fuzhou Tuberculosis Prevention and Control Hospital of Fujian Province, Fuzhou, Fujian, China

  • The Third People's Hospital of Shenzhen, Shenzhen, Guangdong, China

  • Wuhan Institute of Tuberculosis Control (Wuhan Pulmonary Hospital), Wuhan, Hubei, China

  • The Second Hospital of Nanjing, Nanjing, Jiangsu, China

  • Shandong Public Health Clinical Center, Jinan, Shandong, China

  • Huashan Hospital Fudan University, Shanghai, Shanghai Municipality, China

  • Shanghai Pulmonary Hospital - Pneumology, Shanghai, Shanghai Municipality, China

  • Public Health Clinical Center of Chengdu, Chengdu, Sichuan, China

  • National Center for Tuberculosis and Lung Disease, Tbilisi, Georgia

  • Japan Anti-Tuberculosis Association Fukujuji Hospital, Kiyose, Tokyo, Japan

  • IMSP Institutul de Ftiziopneumologie Chiril Draganiuc - Phthisiopneumology, Chisinau, Chisinau City, Moldova

  • Socios en Salud Sucursal Peru, La Molina, Lima region, Peru

  • Centro de Investigación del Hospital de Emergencias de Villa el Salvador, Villa El Salvador, Lima region, Peru

  • Hospital Sergio E. Bernales, Lima, Peru

  • Silang Specialist Medical Center, Silang, Cavite, Philippines

  • Jose B. Lingad Memorial Regional Hospital, San Fernando City, Central Luzon (Region III), Philippines

  • Tropical Disease Foundation, Makati City, National Capital Region, Philippines

  • Lung Center Of The Philippines, Quezon City, National Capital Region, Philippines

  • Synergy Biomed Research Institute, East London, Eastern Cape, South Africa

  • Isango Lethemba TB Res Unit (CHRU) - Jose Pearson TB Hospital, Port Elizabeth, Eastern Cape, South Africa

  • The Aurum Institute - Tembisa Hospital Clinical Research Centre, Johannesburg, Gauteng, South Africa

  • Clinical HIV Research Unit (CHRU) - Helen Joseph Hospital, Johannesburg, Gauteng, South Africa

  • Sizwe Clinical Research Site (CHRU) - Sizwe Tropical Disease Hospital,, Johannesburg, Gauteng, South Africa

  • Setshaba Research Center, Pretoria, Gauteng, South Africa

  • Perinatal HIV Research Unit (PHRU) - Chris Hani Baragwanath Academic Hospital, Soweto, Gauteng, South Africa

  • Centre for the AIDS Programme of Research in South Africa (CAPRISA), Durban, KwaZulu-Natal, South Africa

  • Klerksdorp/Tshepong Hospital Complex, Tshepong Hospital, MDR Unit, Klerksdorp, North West, South Africa

  • The Aurum Institute - Rustenburg, Rustenburg, North West, South Africa

  • Brooklyn Chest Hospital, Belville, Western Cape, South Africa

  • UCT - Lung Infection and Immunity Unit, Cape Town, Western Cape, South Africa

  • UCT Lung Institute, Cape Town, Western Cape, South Africa

  • The Catholic University of Korea, Incheon St. Mary's Hospital, Incheon, Incheon Metropolitan City, South Korea

  • Pusan National University Hospital, Busan, Pusan-Kwangyokshi, South Korea

  • Asan Medical Center - Pulmonology, Seoul, Seoul Teugbyeolsi, South Korea

Study leads

  • Simbarashe G Takuva, MD, MSc.

    Study Director

    Study Sponsor

View source on ClinicalTrials.gov(opens in a new tab)